Treatment of active lupus nephritis with the novel immunosuppressant 15-deoxyspergualin: an open-label dose escalation study

Table 3 Patient characteristics

CRF #	Age (years)	Time since first diagnosis of SLE	Time since first diagnosis of nephritis	LN-WHO type	Pre-treatment of LN within six months before study start
9	20	1.5 years	1.5 years	IV	Prednisone, AZA, MMF, HCQ
10	34	2.5 years	2.5 years	IV	CYC, AZA, Prednisone
11	46	11 years	11 years	IV	Prednisone, MMF
13	39	8. 5 years	4 years	V	Prednisone, MMF
14	20	2 years	4 years	IV	MMF
15	37	7 years	7 years	IV	CYC, Prednisone, CSA, AZA
16	30	17 years	17 years	IV	Prednisone,
17	40	21.5 years	21.5 years	III	AZA, Prednisone, MMF, Immunadsorption
19	20	4.5 years	4.5 years	IV	AZA, MMF, Prednisone, Methylprednisolon, HCQ, Rituximab, Octagam
26	35	9 years	8 years	IV	Prednisone, MMF
31	22, 5	3 years	3 years	IV	CYC, Prednisone
32	42	12 years	12 years	V	AZA, Methylprednisolon
33	31	7 years	7 years	IV	MMF, Prednisone, HCQ
34	19	1 year	1 year	IV	AZA, CYC, Prednison
35	42	10.5 years	10.5 years	IV	Prednisone, AZA
36	30	13 years	4 years	IV	Methylprednisolon AZA
38	22	2.5 years	2.5 years	IV	CYC, Prednisone, HCQ
39	46	2 years	2 years	IV	HCQ, plasmapheresis Prednisolone
42	29	10 years	1 year	V	Prednisone, CSA
49	37, 5	4 years	4 years	V	Prednisone, CSA
50	20	1 year	1 year	IV	Prednisone, AZA, MMF, CYC, Prednisone

AZA, azathioprin; CRF, case report form; CSA, cyclosporine A; CYC, cyclophosphamide; HCQ, hydroxychloroquine; LN, lupus nephritis; MMF, mycophenolic acid; SLE, systemic lupus erythematosus.

ISSN: 1478-6362